Previous close | 0.8800 |
Open | 1.2500 |
Bid | 1.3000 |
Ask | 1.6500 |
Strike | 220.00 |
Expiry date | 2024-05-17 |
Day's range | 1.2500 - 1.7000 |
Contract range | N/A |
Volume | |
Open interest | 747 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.